TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06328192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Breathing Exercises
Description: Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
Study: NCT05595317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-immersive Virtual Reality
Description: The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Non-immersive Virtual Reality
Description: The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
Study: NCT04859868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
Study: NCT06514508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide+G-CSF
Description: Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
Study: NCT05198570

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
Study: NCT05067933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1.1-S
Description: COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets matching the active vaccine tablets
Study: NCT06514508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+G-CSF
Description: Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
Study: NCT06216431

Intervention type: OTHER
Intervention: Physical Evaluations of individuals
Description: Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.

Intervention type: OTHER
Intervention: Physical Evaluations of individuals
Description: Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
Study: NCT06021561

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of pain
Description: Pain will be investigated - type, origin, level
Study: NCT05473312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Sensitization
Description: One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
Study: NCT03955068

Intervention type: OTHER
Group type: OTHER
Intervention: Strict Classic Ketogenic Diet
Description: Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
Study: NCT04795895

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography (US)
Description: US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard routine (SR)
Description: Standard routine (SR)
Study: NCT05477836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiWEndo-assisted colonoscopy
Description: All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.
Study: NCT04813484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kickin it with the Gurlz
Description: This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
Study: NCT06139146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Description: MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises:
Description: Warm up: The cat and camel stretches~Exercises:~* It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~* Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~* Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~* It included a Quadruped position with abdominal bracing for 10 s - 10 reps~* Quadruped position arm lifts with abdominal bracing 10 reps on each side.~* Quadruped position leg lifts with abdominal bracing 10 reps on each side.~* Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~* The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~* Side plank on knees; holding position for 10 s - 5 reps .
Study: NCT05465837

Intervention type: PROCEDURE
Intervention: Tracheostomy
Description: Early and Late Tracheostomy (\</= 10 days: Early and \>10 days: Late)

Intervention type: PROCEDURE
Intervention: Tracheostomy
Description: Early and Late Tracheostomy (\</= 10 days: Early and \>10 days: Late)
Study: NCT06054321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stepwise pharmacotherapy
Description: In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stepwise pharmacotherapy
Description: In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant monotherapy group
Description: In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant monotherapy group
Description: In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
Study: NCT04789837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 MG
Description: Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily plus Celecoxib 200mg capsule
Study: NCT06582550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minor Hand Procedure
Description: Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minor Hand Procedure
Description: Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)
Study: NCT06582316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Training Programme
Description: Train Your Brain (TYB) - group-based cognitive intervention programme for mild cognitive impairments. This programme equips participants with knowledge on cognition and brain health, provide cognitive coping strategies and boost their confidence and maintain independence in daily activities.
Study: NCT04524208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is administered orally at the dose of 60 mg per day..
Study: NCT06306248

Intervention type: OTHER
Intervention: Total sleep deprivation
Description: non pharmacologic treatment for depression
Study: NCT05758428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: 14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
Study: NCT04840225

Intervention type: OTHER
Intervention: Measurement of biomarkers for inflammation and anemia
Description: Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements

Intervention type: OTHER
Intervention: Measurement of biomarkers for inflammation and anemia
Description: Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements

Intervention type: OTHER
Intervention: Measurement of biomarkers for inflammation and anemia
Description: Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements

Intervention type: OTHER
Intervention: Measurement of biomarkers for inflammation and anemia
Description: Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
Study: NCT05651672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5mg, po, 2 weeks on/1 week off, Q3W
Study: NCT06525142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiovisual Intervention
Description: 【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audiovisual Intervention
Description: 【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person.
Study: NCT05050864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: venous sinus stenting
Description: The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosurgical internal ventricular shunt
Description: The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
Study: NCT06453421

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
Study: NCT04565951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA S.A.V.E.
Description: The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones.
Study: NCT04677504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Study: NCT05608551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted trauma-focused therapy
Description: Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard trauma-focused therapy
Description: Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
Study: NCT04984577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection-Low dose
Description: Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection-High dose
Description: Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone Injection
Description: Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection, one dose every 12 hours, continue for 14 days
Study: NCT04108299

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control group
Description: For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS intervention
Description: 2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.